MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, SION had $9,846K increase in cash & cash equivalents over the period. -$15,317K in free cash flow.

Cash Flow Overview

Change in Cash
$9,846K
Free Cash flow
-$15,317K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-20,278 -34,550
Stock-based compensation expense
3,306 4,934
Non-cash operating lease expense
490 981
Amortization of discount on marketable securities
836 1,863
Non-cash expense related to ipr&d acquisition
0 -
Depreciation expense
189 306
Prepaid expenses and other current assets
-177 720
Accounts payable
567 -272
Accrued expenses and other current liabilities
1,684 -2,201
Operating lease liabilities
-529 -1,056
Other assets
0 0
Net cash used in operating activities
-15,230 -34,441
Purchases of property and equipment
87 86
Purchases of marketable securities
54,136 228,011
Maturities of marketable securities
77,325 63,658
Net cash used in investing activities
23,102 -164,439
Proceeds from initial public offering, net of underwriter discounts, commissions and offering costs paid during the period
0 202,071
Proceeds from issuance of series c convertible preferred stock, net of issuance costs
0 0
Payment of deferred offering costs
0 -
Exercise of common stock options
1,974 6
Net cash provided by financing activities
1,974 202,077
Net increase (decrease) in cash, cash equivalents and restricted cash
9,846 3,197
Cash and cash equivalents at beginning of period
38,750 -
Cash and cash equivalents at end of period
51,793 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics, Inc. (SION)